Drugs / CARCIK-CD19
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05869279 | Dec 2023 → Sep 2026 overdue | B-cell chronic lymphocytic leukemia | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03389035 | Dec 2017 → Mar 2021 | acute lymphoblastic leukemia | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CARCIK-CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05869279 ↗ |
| Modality | Cell therapy | “donor-derived CD19 CAR T cells generated with the Sleeping Beauty (SB) transposon and differentiated into cytokine-induced killer (CIK) cells” PMID 32780725 ↗ Nov 2020 |
| Target | CD19 | “Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene” NCT03389035 ↗ |